29 January 2005

Contents

Conference reports

• Paradoxical CD4 response with tenofovir and ddI backbone

• Tenofovir/FTC backbone outperforms AZT/3TC (Combivir) with efavirenz in treatment naive patients; reduced toxicity drives ITT viral efficacy

• Limited stability of lopinavir/r (Kaletra) above 25°C

• Atorvastatin requires dose reduction with tipranavir/r

• Once-daily T-20 is less effective than twice daily: lower potency is related to C trough

• Further genetic link to efavirenz absorption

• Long-term response to FTC in children is similar to adults

• Side effects update: hypersensitivity, heart, bones

Antiretrovirals

• Roche discontinue plans for nelfinavir 625mg formulation

Treatment access

• Generic ARVs and WHO prequalification list

• Cotrimoxazole reduces mortality and morbidity in HIV-positive children: joint WHO/UNAIDS/UNICEF statement

• Equitable access for antiretroviral treatment for women

Guidelines

• US treatment guidelines updated (Jan 2005)

• Updated UK guidelines for HIV and hepatitis coinfection (2005)

Hepatitis coinfection

• Interferon plus 3TC for people with HIV/HBV coinfection

On the web

• 55th Annual Meeting of the American Society for the Study of Liver Diseases (55th AASLD), 29 October – 2 November, 2004, Boston MA

• Conference abstracts and reports

• Update your WHO/EDM bookshelf

• HIV InSite Knowledge Base

• Journal articles online at Medscape

• Facing up to it: Bio-Alcamid as a facial filler to treat lipoatrophy